《大行報告》大和上調潤啤(00291.HK)目標價至82.5元 評級「買入」
大和發表研究報告,指華潤啤酒(00291.HK)上半年純利增107%至43億元人幣,較此前盈喜預期增長100%為高,當中包括出售深圳項目錄17.5億元人民幣收益。該行將目標價由81.3元升至82.5元,重申評級「買入」。
該行指,管理層指上半年產品及包裝成本錄增長,但可被其高端化產品組合所抵銷,期內公司為其主要品牌提價。公司維持今年高端產品按年增長30%以上銷售目標,及冀2025年市場份額錄50%。公司同時計劃將調整產品組合,並關閉部份低效的廠房,並會在策略性地區上建立大型廠房。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.